Bispecific antibody · Immune activation, directed at Epidermal growth factor receptor (EGFR) and CD28 · developed by REGENERON PHARMACEUTICALS
Marlotamig is a bispecific antibody that binds both CD28 on cytotoxic T-lymphocytes and epidermal growth factor receptor (EGFR) on tumor cells. By engaging both, it redirects and activates T cells against EGFR-expressing cells. It is being studied in non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
Non Small Cell Lung CancerNSCLC
Updated Nov 8, 2026. Something wrong or missing? Report it on the REGN page.
See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REGN catalysts and pipeline →